ASSESSING PAKISTANI PHYSICIANS’ KNOWLEDGE AND EXPERIENCE WITH OFF-LABEL USE OF MEDICINES
Article Sidebar
Main Article Content
Abstract
Background: Off-label prescribing, the use of pharmaceutical drugs beyond their approved indications, is a growing practice globally and raises important questions regarding safety, efficacy, and regulatory oversight. Despite its widespread application in various specialties, many healthcare providers remain unaware of the legal and ethical implications of such use. In countries like Pakistan, where formal regulations are lacking, assessing physician knowledge and behavior becomes crucial to ensure patient safety and informed clinical decision-making.
Objective: To evaluate the knowledge, attitude, and practice (KAP) of physicians in Pakistan regarding off-label drug use and identify gaps requiring policy and educational interventions.
Methods: This cross-sectional study employed a self-developed, pre-validated questionnaire distributed to 377 MBBS-qualified physicians across various hospitals in Islamabad and Rawalpindi between December 2023 and May 2024. A total of 210 valid responses were collected (response rate: 56%). The questionnaire comprised demographic data and 20 knowledge and experience-based items. Data were analyzed using SPSS version 25. Categorical variables were summarized in frequencies and percentages, and continuous variables were presented as means ± standard deviations. Fisher’s exact test and chi-square test were used to assess associations, with p ≤ 0.05 considered statistically significant.
Results: Among the respondents, 55.7% were male and 44.3% were female; 83% were specialists and 17% were general practitioners. While 80% were familiar with the concept of off-label prescribing, only 21% correctly defined it. A total of 55.8% had prescribed off-label medications, yet 45.7% believed they had never done so, reflecting a knowledge gap. Moreover, 58% perceived off-label use as illegal, and 86.7% recommended the need for formal guidelines. Mean KAP scores were moderate across all domains, with significant differences based on gender, specialty, and experience (p<0.05).
Conclusion: Physicians in Pakistan demonstrate moderate understanding and limited experience regarding off-label prescribing. The findings highlight an urgent need for regulatory frameworks and targeted education to ensure evidence-based and safe off-label drug use.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Svitlana, D., Kateryna, K., Tsyvunin, V., Viktoriia, H., Anatolij, L., Olexandr, V., & Dmitriy, Z. Positive and negative aspects of the off-label drugs use. Pharmacologyonline. 2021; 2:1179-85.
Shakeel, S., Iffat, W., Qamar, A., Nesar, S., Butt, F., Siddiqui, S. N., & Rehman, H. Assessment of Knowledge, Attitude, and Practice of Obstetricians and Gynecologists Toward Off-Label Medicine Use in Female Reproductive Health Issues. Front. Public Health. 2022 Mar 24; 10:829339.
Shakeel, S., Hassali, M. A., Rehman, H., Rehman, A. U., & Muneswarao, J. Knowledge, attitude, and practice towards biosimilars and interchangeable products: a prescriptive insight by the pharmacists. Int. J. Gen. Med. 2020; 1075-1082.
Husaini DC, Abubakar Y, Mphuthi DD. Stockpiling on off-label medicines in preparation for COVID-19 in Belize: a qualitative study. Int. J. Med. Sci. 2021. 26;8.
Shakeel S, Nesar S, Rehman H, Jamil K, Mallick IA, Mustafa MS, Anwar M, Jamshed S. Patterns and predictors of off-label drug prescribing in psychiatric practice: a qualitative study. Pharmacy. 2021 ;9(4):203.
Drenska M, Naseva E, Getov I. Physician's knowledge and experience with the off-label use of medicines. Biotechnol. Biotechnol. Equip. 2021 ;35(1):111-6.
Radojević S, Krajnović D. Use of off-label medicines in the pediatric population. TMG. 2021;46(2):86-92.
Onavbavba G, Alemede VO, Uzu IF. Off-Label Use of Medicines in Children Attending a Secondary Healthcare Facility in Federal Capital Territory. J. Med. Health. 2021;173.
Shah, H.P., et al., Assessing National Trends and Perceived Safety of Off-Label Ciprofloxacin-Dexamethasone Use by Pediatric Otolaryngologists. Laryngoscope, 2024. 134(6): p. 2922-2930.
Drapkina, O.M., et al., Assessment of Awareness and Experience of Using off-label Drugs by Doctors of Clinical Specialties. Kardiologiia, 2021. 61(5): p. 41-50.
Shakeel, S., et al., Assessment of Knowledge, Attitude, and Practice of Obstetricians and Gynecologists Toward Off-Label Medicine Use in Female Reproductive Health Issues. Front Public Health, 2022. 10: p. 829339.
De Bondt, E., et al., Awareness of national dementia guidelines and management of oldest-old and frail people living with dementia: a European survey of geriatricians. Eur Geriatr Med, 2025. 16(2): p. 527-539.
McKibbin, R., The effect of RCTs on drug demand: Evidence from off-label cancer drugs. J Health Econ, 2023. 90: p. 102779.
Meng, M., et al., Guideline for the management of pediatric off-label use of drugs in China (2021). BMC Pediatr, 2022. 22(1): p. 442.
Chansky, M.C., et al., Influence of data disclosures on physician decisions about off-label uses: findings from a qualitative study. BMC Prim Care, 2022. 23(1): p. 87.
Weldon, E., et al., Medical Malpractice Litigation Due to Off-Label Use of Bone Morphogenetic Protein. Spine (Phila Pa 1976), 2023. 48(22): p. 1575-1580.
Andersen, N.M., et al., Medical practitioners' experiences and considerations when managing sleep medication for adolescents and young adults. Scand J Prim Health Care, 2025. 43(1): p. 120-130.
Rusz, C.M., et al., Off-Label Medication: From a Simple Concept to Complex Practical Aspects. Int J Environ Res Public Health, 2021. 18(19).
van Hoorn, C.E., et al., Off-label use of dexmedetomidine in paediatric anaesthesiology: an international survey of 791 (paediatric) anaesthesiologists. Eur J Clin Pharmacol, 2021. 77(4): p. 625-635.
Müller, L., et al., Off-label use of quetiapine in nursing homes: Does medical specialty of prescribing physicians play a role? Br J Clin Pharmacol, 2020. 86(7): p. 1444-1445.
Ebm, C., et al., Potential harm caused by physicians' a-priori beliefs in the clinical effectiveness of hydroxychloroquine and its impact on clinical and economic outcome - A simulation approach. J Crit Care, 2021. 62: p. 138-144.
Han, S.H., et al., Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss. Aesthet Surg J, 2024. 44(4): p. Np279-np306.
Drabiak, K., The Problem with Using Medical Boards to Regulate Misinformation. J Leg Med, 2023. 43(1-2): p. 3-18.
Okuyama, E., et al., Radiologist expertise and responsibilities for off-label use of Urografin before the change in indication by medical health insurance. Jpn J Radiol, 2023. 41(8): p. 909-910.
van der Zanden, T.M., L. Schrier, and S.N. de Wildt, [A step-by-step guide for safe off-label prescribing]. Ned Tijdschr Geneeskd, 2021. 165.